sorafenib generic — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has FLT3-ITD mutation-positive disease as detected by an approved test
• Medication is used in combination with azacitidine or decitabine OR patient has had an allogeneic stem cell transplant and is in remission

Approval duration

1 year